Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
A pharmaceutical composition comprising an active contraceptive drug and one or more pharmaceutically-acceptable excipients. The pharmaceutical composition, when subjected to an in vitro dissolution test according to the USP XXIII Paddle Method, results in no more than 50% of said active drug initially present being dissolved within 30 minutes, and at least 50% of the active drug being dissolved in a time range from about 3 hours to about 4 hours. The pharmaceutical composition is administered daily to a patient having a BMI of about 25 kg/m 2 or more for at least a portion of a treatment cycle. The pharmaceutical composition does not cause a number of days of bleeding events in the patient exceeding an average of 15% per treatment cycle in consecutive treatment cycles of administration after an initial treatment cycle of administration.
1. A method of providing contraception in a patient having a BMI of 30 kg/m 2 or more and bleeding events, the method comprising:
administering a pharmaceutical composition comprising 2.5 mg to 5.5 mg crystalline of drospirenone and one or more pharmaceutically-acceptable excipients to a patient having a BMI of 30 kg/m 2 or more for an initial treatment cycle and for subsequent consecutive treatment cycles, the pharmaceutical composition being administered daily for at least a portion of the initial and subsequent consecutive treatment cycles;
wherein the administering results in a limited number of days of bleeding events per treatment cycle in at least one of the subsequent consecutive treatment cycles.
2. The method of claim 1 , wherein the limited number of days of bleeding events in the at least one of the subsequent consecutive treatment cycles of administration does not exceed about 13% per treatment cycle.
3. The method of claim 1 , wherein the limited number of days of bleeding events in the at least one of the subsequent consecutive treatment cycles of administration does not exceed about 11% per treatment cycle.
4. The method of claim 1 , wherein the limited number of days of bleeding events in the at least one of the subsequent consecutive treatment cycles of administration does not exceed about 10% per treatment cycle.
5. The method of claim 1 , wherein the limited number of days of bleeding events in the at least one of the subsequent consecutive treatment cycles of administration does not exceed about 7%.
6. The method of claim 1 , wherein the limited number of days of bleeding events in the at least one of the subsequent consecutive treatment cycles of administration does not exceed about 5%.
7. The method of claim 1 , wherein the number of days of limited bleeding events in one of a second through ninth treatment cycles is reduced by about 44% to about 85% as compared to the initial treatment cycle.
8. The method of claim 7 , wherein the number of days of limited bleeding events in one of the second through ninth treatment cycle is reduced by about 50% to about 75% as compared to the initial treatment cycle.
9. The method of claim 1 , wherein the number of days of limited bleeding events in one of the second through the ninth treatment cycle is reduced by at least about 20% as compared to the initial treatment cycle.
10. The method of claim 9 , wherein the number of days of limited bleeding events in one of the second through ninth treatment cycle is reduced by at least about 40% as compared to the initial treatment cycle.
11. The method of claim 10 , wherein the number of days of limited bleeding events in one of the second through the ninth treatment cycle is reduced by at least about 60% as compared to the initial treatment cycle.
12. The method of claim 1 , wherein the administering causes weight loss in the patient measured from the initial treatment cycle and an end of one of a first through thirtieth subsequent consecutive treatment cycles.
13. The method of claim 12 , wherein the weight loss is about 1 kg to about 10 kg.
14. The method of claim 12 , wherein the weight loss is about 1 kg to about 4 kg.
15. The method of claim 12 , wherein the weight loss results in a reduction in the patient's BMI of about 1% to about 20%.
16. The method of claim 12 , wherein the weight loss results in a reduction in the patient's BMI of about 1% to about 5%.
17. The method of claim 1 , wherein the administration of the pharmaceutical composition causes a decrease in a resting heart rate in the patient as measured from the initial treatment cycle and an end of one of a first through thirtieth subsequent consecutive treatment cycles.
18. The method of claim 17 , wherein the decrease in the resting heart rate is at least 5 beats per minute.
19. The method of claim 18 , wherein the decrease in the resting heart rate is at least 15 beats per minute.
20. The method of claim 17 , where the decrease in the resting heart rate is about 2% to about 20%.
21. The method of claim 20 , wherein the decrease in the resting heart rate is about 5% to about 7%.
22. The method of claim 1 , wherein the subsequent consecutive treatment cycles are a first to thirtieth treatment cycles following the initial treatment cycle of administration.
23. The method of claim 1 , wherein the drospirenone is non-micronized.
24. The method of claim 1 , wherein the drospirenone is provided in a particle form.
25. The method of claim 24 , wherein the particle form has a specific surface area from about 2,000 cm 2 /g to about 8,500 cm 2 /g.
26. The method of claim 24 , wherein the particle form has a diameter of about 200 μm or less.
27. The method of claim 24 , wherein the particle form has a d 50 in the range of about 10 μm to about 60 μm.
28. The method of claim 24 , wherein a particle size distribution of the active contraceptive drug is characterized by:
(i) a d 90 particle size less than about 100 μm, and/or
(ii) a d 50 particle size ranging from about 10 μm to about 60 μm, and/or
(iii) a d 10 particle size more than about 3 μm.
29. The method of claim 28 , wherein the d 90 particle size ranges from about 20 μm to about 40 μm.
30. The method of claim 28 , wherein the d 50 particle size ranges from about 10 μm to about 30 μm.
31. The method of claim 28 , wherein the d 10 particle sizes range from about 3 μm to about 9 μm.
32. The method of claim 1 , wherein the crystalline drospirenone is present in an amount of 2 mg to 6 mg.
33. The method of claim 32 , wherein the crystalline drospirenone is present in an amount of 4 mg.
34. The method of claim 1 , wherein the pharmaceutical composition does not include estrogen.
35. The method of claim 34 , wherein the pharmaceutical composition is provided in a single daily oral tablet dosage form.
36. The method of claim 35 , wherein the pharmaceutical composition comprising 3.2 mg to 4.8 mg of crystalline drospirenone.
37. The method of claim 36 , wherein the pharmaceutical composition provides a pharmacokinetic profile for the drospirenone having: i) T max ranging from about 2.2 hours to 6 hours and ii) a mean C max which is less than 30 ng/ml when orally administered to the patient under fasting conditions.
38. The method of claim 37 , wherein the pharmacokinetic profile for the drospirenone additionally comprises an AUC 0h-tlast which is at least 300 ng·h/ml.
39. The method of claim 37 , wherein the mean C max ranges from 15 ng/ml to 30 ng/ml.
40. The method of claim 36 , wherein when the pharmaceutical composition is subjected to an in vitro dissolution test according to the USP XXIII Paddle Method: no more than 50% of the drospirenone initially present in the pharmaceutical composition is dissolved within 30 minutes, and at least 50% of the drospirenone is dissolved in a time range from 3 hours to 4 hours.